Basal Cell Carcinoma Treatment Market - Global Industry Analysis

Basal Cell Carcinoma Treatment Market By Treatment Type (Radiation Therapy, Drugs, and Surgery), By End-User (Specialty Clinics, Hospitals, and Others), and By Region – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028

Published Date: 30-May-2022 Category: Pharmaceutical Report Format : PDF Pages: 185 Report Code: ZMR-3297 Status : Published

The global basal cell carcinoma treatment market had total revenue of roughly USD 5.53 billion in 2021 and is predicted to grow to around USD 12.8 billion by 2028, with a CAGR of around 8.1 percent.

Description

Industry Prospective:

The global basal cell carcinoma treatment market had total revenue of roughly USD 5.53 billion in 2021 and is predicted to grow to around USD 12.8 billion by 2028, with a CAGR of around 8.1 percent. The study looks at the market for basal cell carcinoma treatment drivers, restraints, and challenges, as well as their impact on demand during the projection period. The study also explores new opportunities in the market for treating basal cell carcinoma.

Basal Cell Carcinoma Treatment Market: Overview

Basal cell carcinoma is a type of skin cancer that is commonly found in all types of cancers. Basal cell carcinoma is caused by the uncontrolled development of basal cells. Since basal cell carcinoma has a slower growth rate, it is curable and can cause relatively little damage if identified early and treated. The malignancy must be removed in order to treat basal cell carcinoma. Treatment is determined by the location, size, and type of cancer. The type of treatment depends on whether the carcinoma is a newly diagnosed or reoccurring cancer.

COVID-19 Impact:

COVID-19 had an impact on the economy in three ways: directly impacting demand & production, disrupting distribution networks, and having a financial impact on financial & business markets. Furthermore, the COVID-19 pandemic is posing significant difficulties to competitors in the global basal cell carcinoma treatment market on multiple fronts. The supply of raw materials required for making drug formulations is a big difficulty due to transportation anomalies. In addition to this, a decrease inpatient visit, a halt in clinical trials, and temporary closure of operations of major players are also some of the key factors limiting the market growth during the Covid-19 pandemic. However, post-pandemic, the market is expected to grow at a rapid rate.

Global Basal Cell Carcinoma Treatment Market

Basal Cell Carcinoma Treatment Market: Growth Drivers

Increasing prevalence of basal cell carcinoma to drive the market growth

Skin cancers (the majority of which are basal and squamous cell skin tumors) are the most frequent of all cancers. Each year, roughly 5.4 million squamous and basal cell skin malignancies are detected in the United States, according to one study. Basal cell tumors account for about eight out of ten of these malignancies. For many years, the incidence of these cancers has been rising. This is likely due to a combination of increased sun exposure and improved skin cancer detection. Thus, the rising prevalence of basal cell carcinoma is among the primary factor boosting the growth of the market. In addition to this, developing healthcare infrastructure and growing initiatives for awareness regarding the early diagnosis of diseases are estimated to foster market growth.

Basal Cell Carcinoma Treatment Market: Restraints

High costs related to basal cell carcinoma treatment to hinder the market growth

The cost for basal cell carcinoma depends on its stage and location. Radiation, chemotherapy, and surgery are some of the treatment options for this cancer. Some expenses are covered by insurance, but out-of-pocket expenses might be hefty. Treatment for all types of skin cancer, according to the CDC, costs approximately $8 billion each year. By 2030, the organization estimates that treating new patients will cost $1.6 billion each year. Many cancer medications, particularly immunotherapy treatments, are quite costly. It is also being observed that persons with metastatic cancer spend more than 6 times more on care in the 12 months after their initial diagnosis than those with localized cancer. Also, one or maybe more chemotherapeutic drugs are frequently used to treat skin cancer. Many are brand-new drugs with a hefty price tag. New cancer treatments, according to the National Cancer Institute, can cost over $100,000 per patient annually. Thus, such high costs associated with the treatment of basal cell carcinoma are likely to impede the growth of the global basal cell carcinoma treatment market.

Basal Cell Carcinoma Treatment Market: Opportunities

Heavy investment by major players in the development of drugs and R&D activities to fuel market

As botanical drugs were granted FDA approval in 2004, an increasing number of established and developing companies, notably large pharmaceutical companies, have begun to produce plant-derived and botanical drugs. As a result, both public and private investment is increasing in this industry. Botanicals are expected to rise rapidly as advances in plant culture technologies improve efficiency and lower development costs. As a result, major medical organizations are expected to increase their investments in basal cell carcinomas drugs & therapies, thereby propelling the global basal cell carcinoma treatment market growth forward during the forecast period.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Basal Cell Carcinoma Treatment Market: Challenges.

Management of advanced and high-risk basal cell carcinoma is a challenge for the market

For advanced basal cell carcinoma, Hedgehog inhibitors and surgical treatments, particularly Mohs surgery, have ruled the therapy landscape. However, not every patient is suitable for surgery, and for Hedgehog inhibitors, tolerance and progression difficulties can make long-term disease care difficult. Some BCC patients progress to a stage where they face considerable management issues. Recurring, locally advanced, or metastatic BCC, as well as tumors that exist in anatomical places where surgical treatment would result in substantial deformity, are examples of such situations. Thus, management of advanced BCC coupled with strict regulatory standards for the approval of new drugs acts as major challenge to the growth of the market.

Basal Cell Carcinoma Treatment Market: Segmentation

The global basal cell carcinoma treatment market is categorized into treatment type, end-user, and region. Based on the treatment type, the global market is divided into radiation therapy, drugs, and surgery. The end-user segment consists of specialty clinics, hospitals, and others.

Recent Developments

  • In June 2021, Sanofi and Regeneron's PD-1 inhibitor Libtayo® has received approval from the European Commission to treat people with locally advanced or metastatic basal cell carcinoma who have advanced or are intolerant to a Hedgehog pathway inhibitor.
  • In June 2020, Provectus unveiled approval from The Indian Patent Office for its patent application for the combination of novel autolytic cancer immunotherapy PV-10® with systemic immunomodulatory therapy, such as immune checkpoint inhibition (CB). PV-10, which is based on small molecules, is injected into superficial melanoma and non-melanoma skin cancer including squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma via cutaneous intratumoral injection.

Basal Cell Carcinoma Treatment Market: Regional Landscape

North America to lead the market during the forecast period

North America is expected to dominate the global basal cell carcinoma treatment market throughout the projected period. This is attributable to key aspects such as the favorable reimbursement policies, increased awareness of advanced treatments, the growing senior population, and the region's high prevalence of basal cell carcinoma. The United States is anticipated to hold the major share owing to the presence of major players, and well-developed healthcare infrastructure. Asia Pacific is expected to grow at a rapid rate during the forecast period.

Basal Cell Carcinoma Treatment Market: Competitive Landscape

The major players operating in the global basal cell carcinoma treatment market include Sun Pharmaceuticals Ltd, Mylan N.V., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc, Merck and Co. Inc., Sanofi, Strides Arcolab Ltd., Perrigo Company plc, Allergan, Inc., and Bausch Health Companies among others.

Global basal cell carcinoma treatment market is segmented as follows:

By Treatment Type

  • Surgery
  • Drugs
  • Radiation Therapy

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Basal Cell Carcinoma Treatment Market, (2022 - 2028) (USD Billion)
    • 2.2 Global Basal Cell Carcinoma Treatment Market : snapshot
  • Chapter 3. Global Basal Cell Carcinoma Treatment Market - Industry Analysis
    • 3.1 Basal Cell Carcinoma Treatment Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Increasing prevalence of basal cell carcinoma to drive the market growth
    • 3.3 Market Restraints
      • 3.3.1. High costs related to basal cell carcinoma treatment to hinder the market growth
    • 3.4 Market Opportunities
      • 3.4.1. Heavy investment by major players in the development of drugs and R&D activities to fuel market
    • 3.5 Market Challenges
      • 3.5.1. Management of advanced and high-risk basal cell carcinoma is a challenge for the market
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Treatment Type
      • 3.7.2 Market attractiveness analysis By End User
  • Chapter 4. Global Basal Cell Carcinoma Treatment Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Basal Cell Carcinoma Treatment Market: company market share, 2021
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Basal Cell Carcinoma Treatment Market - Treatment Type Analysis
    • 5.1 Global Basal Cell Carcinoma Treatment Market overview: By Treatment Type
      • 5.1.1 Global Basal Cell Carcinoma Treatment Market share, By Treatment Type, 2021 and 2028
    • 5.2 Surgery
      • 5.2.1 Global Basal Cell Carcinoma Treatment Market by Surgery, 2022 - 2028 (USD Billion)
    • 5.3 Drugs
      • 5.3.1 Global Basal Cell Carcinoma Treatment Market by Drugs, 2022 - 2028 (USD Billion)
    • 5.4 Radiation Therapy
      • 5.4.1 Global Basal Cell Carcinoma Treatment Market by Radiation Therapy, 2022 - 2028 (USD Billion)
  • Chapter 6. Global Basal Cell Carcinoma Treatment Market - End User Analysis
    • 6.1 Global Basal Cell Carcinoma Treatment Market overview: By End User
      • 6.1.1 Global Basal Cell Carcinoma Treatment Market share, By End User, 2021 and 2028
    • 6.2 Hospitals
      • 6.2.1 Global Basal Cell Carcinoma Treatment Market by Hospitals, 2022 - 2028 (USD Billion)
    • 6.3 Specialty Clinics
      • 6.3.1 Global Basal Cell Carcinoma Treatment Market by Specialty Clinics, 2022 - 2028 (USD Billion)
    • 6.4 Others
      • 6.4.1 Global Basal Cell Carcinoma Treatment Market by Others, 2022 - 2028 (USD Billion)
  • Chapter 7. Basal Cell Carcinoma Treatment Market - Regional Analysis
    • 7.1 Global Basal Cell Carcinoma Treatment Market Regional Overview
    • 7.2 Global Basal Cell Carcinoma Treatment Market Share, by Region, 2021 & 2028 (USD Billion)
    • 7.3. North America
      • 7.3.1 North America Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
        • 7.3.1.1 North America Basal Cell Carcinoma Treatment Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 North America Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028
      • 7.4.1 North America Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028 (USD Billion)
    • 7.5 North America Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028
      • 7.5.1 North America Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028 (USD Billion)
    • 7.4. Europe
      • 7.4.2 Europe Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
        • 7.4.2.1 Europe Basal Cell Carcinoma Treatment Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Europe Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028
      • 7.4.1 Europe Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028 (USD Billion)
    • 7.5 Europe Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028
      • 7.5.1 Europe Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028 (USD Billion)
    • 7.5. Asia Pacific
      • 7.5.3 Asia Pacific Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
        • 7.5.3.1 Asia Pacific Basal Cell Carcinoma Treatment Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Asia Pacific Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028
      • 7.4.1 Asia Pacific Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028 (USD Billion)
    • 7.5 Asia Pacific Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028
      • 7.5.1 Asia Pacific Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028 (USD Billion)
    • 7.6. Latin America
      • 7.6.4 Latin America Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
        • 7.6.4.1 Latin America Basal Cell Carcinoma Treatment Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 Latin America Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028
      • 7.4.1 Latin America Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028 (USD Billion)
    • 7.5 Latin America Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028
      • 7.5.1 Latin America Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028 (USD Billion)
    • 7.7. The Middle-East and Africa
      • 7.7.5 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
        • 7.7.5.1 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, by Country, 2022 - 2028 (USD Billion)
    • 7.4 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028
      • 7.4.1 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, by Treatment Type, 2022 - 2028 (USD Billion)
    • 7.5 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028
      • 7.5.1 The Middle-East and Africa Basal Cell Carcinoma Treatment Market, by End User, 2022 - 2028 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1 Sun Pharmaceuticals Ltd
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Mylan N.V.
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 F. Hoffmann-La Roche Ltd.
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Valeant Pharmaceuticals International Inc
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Merck and Co. Inc.
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Sanofi
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Strides Arcolab Ltd.
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Perrigo Company plc
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 Allergan Inc.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Bausch Health Companies
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Basal Cell Carcinoma Treatment Market attractiveness, By Treatment Type
  • 6. Global Basal Cell Carcinoma Treatment Market attractiveness, By End User
  • 7. Global Basal Cell Carcinoma Treatment Market share by Treatment Type, 2022 and 2028 (USD Billion)
  • 8. Global Basal Cell Carcinoma Treatment Market by Surgery, 2022 - 2028 (USD Billion)
  • 9. Global Basal Cell Carcinoma Treatment Market by Drugs, 2022 - 2028 (USD Billion)
  • 10. Global Basal Cell Carcinoma Treatment Market by Radiation Therapy, 2022 - 2028 (USD Billion)
  • 11. Global Basal Cell Carcinoma Treatment Market share by End User, 2022 and 2028 (USD Billion)
  • 12. Global Basal Cell Carcinoma Treatment Market by Hospitals, 2022 - 2028 (USD Billion)
  • 13. Global Basal Cell Carcinoma Treatment Market by Specialty Clinics, 2022 - 2028 (USD Billion)
  • 14. Global Basal Cell Carcinoma Treatment Market by Others, 2022 - 2028 (USD Billion)
  • 15. Global Basal Cell Carcinoma Treatment Market share, by Region, 2022 and 2028
  • 16. North America Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
  • 17. Europe Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
  • 18. Asia Pacific Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
  • 19. Latin America Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)
  • 20. The Middle-East and Africa Basal Cell Carcinoma Treatment Market, 2022 - 2028 (USD Billion)

Table Of Tables

  • 1. Global Basal Cell Carcinoma Treatment Market: Snapshot
  • 2. Drivers of the Basal Cell Carcinoma Treatment Market: impact analysis
  • 3. North America Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 4. North America Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 5. U.S. Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 6. U.S. Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 7. Canada Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 8. Canada Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 9. Europe Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 10. Europe Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 11. Germany Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 12. Germany Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 13. France Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 14. France Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 15. U.K. Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 16. U.K. Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 17. Italy Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 18. Italy Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 19. Spain Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 20. Spain Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 21. Rest of Europe Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 22. Rest of Europe Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 23. Asia Pacific Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 24. Asia Pacific Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 25. China Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 26. China Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 27. Japan Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 28. Japan Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 29. India Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 30. India Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 31. South Korea Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 32. South Korea Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 33. South-East Asia Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 34. South-East Asia Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 35. Rest of Asia Pacific Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 36. Rest of Asia Pacific Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 37. Latin America Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 38. Latin America Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 39. Brazil Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 40. Brazil Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 41. Mexico Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 42. Mexico Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 43. Rest of Latin America Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 44. Rest of Latin America Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 45. The Middle-East and Africa Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 46. The Middle-East and Africa Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 47. GCC Countries Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 48. GCC Countries Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 49. South Africa Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 50. South Africa Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)
  • 51. Rest of Middle-East Africa Basal Cell Carcinoma Treatment Market revenue, By Treatment Type, 2022 - 2028 (USD Billion)
  • 52. Rest of Middle-East Africa Basal Cell Carcinoma Treatment Market revenue, By End User, 2022 - 2028 (USD Billion)

Methodology

Free Analysis

Basal cell carcinoma is a type of nonmelanocytic cancer that arises from basal cells present in the lower epidermis. It does not spread to other parts of the body but in rare cases, it can metastasize to other body parts and it is generally caused by the exposure to ultraviolet rays. Immunosuppressant drugs are further expected to increase the probability of basal cell carcinoma as the immune system is suppressed by these drugs. Basal cell carcinoma can be life-threatening in rare conditions and white people are considered more vulnerable to basal cell carcinoma. The symptom for basal cell carcinoma includes waxy papules with a central depression and bleeding can also be observed from those papules. There are various treatment options available for the basal cell carcinoma such as surgery, drugs, and others such as radiation therapy and it may take some time to get completely cured.

The major factors driving the growth of basal cell carcinoma treatment market over the forecast period are an increase in various types of skin disorders coupled with melanoma and others. Increased prevalence of cutaneous malignancies is further expected to drive the growth of basal cell carcinoma treatment market. As per the American Cancer Society 2018 report, an estimated 91,270 adults (55,150 men and 36,120 women) in the United States were diagnosed with melanoma of the skin. Melanoma is the fifth most common cancer among men and the sixth most common cancer in women. Australia is expected to have a number of cases for basal cell carcinoma as compared to other countries. Furthermore, increase in geriatric population, increased prevalence, and favorable reimbursement policies are further expected to support the growth of basal cell carcinoma treatment market.

Global Basal Cell Carcinoma Treatment Market

Basal cell carcinoma treatment market is segmented on the basis of treatment type, end-user, and region. Treatment type segment is further classified into surgery, drugs, and others. Surgery segment is expected to grow rapidly over the forecast period. Based on the end user, the market is segmented into hospitals, specialty clinics, and others. Hospitals and specialty clinics are expected to grow significantly in the near future.

Basal cell carcinoma treatment is regionally segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to contribute to the major market share which is expected to be closely followed by Europe over the forecast period. The major contribution of these regions is due to the advanced medical and healthcare facilities and infrastructure. The Asia Pacific is expected to grow moderately over the forecast period. Latin America and the Middle East and Africa are expected to develop at a considerable rate within the forecast period.

Some of the key players of basal cell carcinoma treatment market include Merck & Co. Inc., Valeant Pharmaceuticals International Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., Sun Pharmaceuticals Ltd., Allergan, Inc., Perrigo Company plc, and Strides Arcolab Ltd., amongst others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Rising prevalence of basal cell carcinoma is among the primary factor boosting the growth of the market. In addition to this, developing healthcare infrastructure and growing initiatives for awareness regarding the early diagnosis of diseases are estimated to foster market growth.

According to the Zion Market Research report, the global basal cell carcinoma treatment market was worth about 5.53 (USD billion) in 2021 and is predicted to grow to around 12.8 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 8.1 percent.

North America is expected to dominate the global basal cell carcinoma treatment market throughout the projected period. This is attributable to key aspects such as the favorable reimbursement policies, increased awareness of advanced treatments, the growing senior population, and the region's high prevalence of basal cell carcinoma. The United States is anticipated to hold the major share owing to the presence of major players, and well-developed healthcare infrastructure.

The major players operating in the global basal cell carcinoma treatment market include Sun Pharmaceuticals Ltd, Mylan N.V., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc, Merck and Co. Inc., Sanofi, Strides Arcolab Ltd., Perrigo Company plc, Allergan, Inc., and Bausch Health Companies among others.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed